Thursday's Health Winners & Losers
Earnings were good to a few health companies, such as Immucor (BLUD), but not as nice to others on a gloomy Thursday in the market.
Immucor reported net income of $18.2 million, up 51% from $12.1 million for the same quarter last year. The company said it earned 26 cents a share. The Thomson Financial consensus target was 22 cents a share. The company gained $2.05, or 7.2%, to $30.63.
Also up, Affymetrix (AFFX) reported earnings after market close on Wednesday. The company said revenue rose 10% to $88.3 million, and it reported net income of $1.2 million, or 2 cents a share, compared with a loss of $10.1 million, or 15 cents a share, during the same period in 2006.
Looking ahead, Affymetrix is predicting revenue from $365 million to $385 million for fiscal 2007, and gross margins around 60%. Shares climbed $1.44, or 5.8%, to $26.30.But on the down side, Bristol-Myers Squibb (BMY) earned 37 cents a share, excluding one-time items, which is one penny better than the consensus of analysts polled by Thomson First Call. Revenue of $4.93 billion matched expectations. The company raised guidance for the year, but investors seemed dissatisfied -- shares fell $1.33, or 4.2%, to $30.25. Bristol-Myers Squibb and AstraZeneca are both components of the Amex Pharmaceutical index, which was down 9.42, or 2.8%, to 340.44.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV